Progression of amiodarone induced cataracts.
Amiodarone hydrochloride is a potent antiarrhythmic agent recently approved for use by the Food and Drug Administration. Anterior subcapsular lens opacities were observed in seven of fourteen patients treated with moderate to high doses of amiodarone at the Veterans Administration Medical Center in San Francisco in 1982. The present report summarizes the present status of these same fourteen patients ten years later. Anterior subcapsular lens opacities developed or progressed in all patients continuing treatment with this antiarrhythmic agent during the following ten year interval. Although Snellen visual acuities are not decreased, subtle visual impairment is present as measured by contrast sensitivity measurements with and without glare. This decrease in visual acuity is not a contraindication for therapy with this potentially life saving drug.
Flach
A J
AJ
Department of Ophthalmology, Veterans Administration Hospital, San Francisco, Calif.
Dolan
B J
BJ
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002386:Cataract / Q000139:chemically induced* / Q000473:pathology; D015350:Contrast Sensitivity; D005500:Follow-Up Studies; D006801:Humans; D007908:Lens, Crystalline / Q000187:drug effects / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D014786:Vision Disorders / Q000175:diagnosis; D014792:Visual Acuity
D000638:Amiodarone